关于“大疱性类天疱疮中糖尿病患病率的变化：是二肽基肽酶 -4 抑制剂所致”的评论 - Suppr

Suppr

超能文献

Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.

作者信息

Fania L, Di Zenzo G, Mazzanti C, Abeni D

机构信息

Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.

出版信息

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.

DOI:10.1111/jdv.14965

PMID:29569809

Abstract

摘要

相似文献

Commentary on 'Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors'.关于“大疱性类天疱疮中糖尿病患病率的变化：是二肽基肽酶 -4 抑制剂所致”的评论

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):e439-e440. doi: 10.1111/jdv.14965. Epub 2018 May 3.

Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study".关于“除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究”的评论

J Am Acad Dermatol. 2018 Dec;79(6):e111-e112. doi: 10.1016/j.jaad.2018.06.043.

Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'".回复：“对‘除二肽基肽酶-4抑制剂外的口服降糖药与大疱性类天疱疮无关：一项芬兰全国性病例对照研究’的评论”

J Am Acad Dermatol. 2018 Dec;79(6):e113-e114. doi: 10.1016/j.jaad.2018.06.042.

[Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal].大疱性类天疱疮与二肽基肽酶-4抑制剂之间的关联及其撤药的影响

Aten Primaria. 2023 Apr;55(4):102586. doi: 10.1016/j.aprim.2023.102586. Epub 2023 Feb 24.

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid.合并用药与二肽基肽酶-4抑制剂相关的大疱性类天疱疮。

An Bras Dermatol. 2021 Nov-Dec;96(6):782-784. doi: 10.1016/j.abd.2020.10.010. Epub 2021 Sep 30.

Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database.

J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e879-e881. doi: 10.1111/jdv.18975. Epub 2023 Feb 27.

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.与使用二肽基肽酶-4抑制剂相关的大疱性类天疱疮。

CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.

Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.

J Am Acad Dermatol. 2019 Jun;80(6):e189-e190. doi: 10.1016/j.jaad.2019.01.086. Epub 2019 Feb 7.

Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.二肽基肽酶-4抑制剂诱发大疱性类天疱疮并伴有获得性反应性穿通性皮病

Actas Dermosifiliogr. 2022 Oct;113(9):914-915. doi: 10.1016/j.ad.2021.01.023. Epub 2022 May 27.

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.病例报告：二肽基肽酶-4 抑制剂相关性大疱性类天疱疮发病后出现多种疾病特异性抗体

Front Immunol. 2022 Mar 3;13:843480. doi: 10.3389/fimmu.2022.843480. eCollection 2022.

引用本文的文献

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验

Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.

Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.二肽基肽酶-4 抑制剂治疗的糖尿病患者并发大疱性类天疱疮：硬币的另一面。

J Transl Med. 2021 Dec 20;19(1):520. doi: 10.1186/s12967-021-03192-8.

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.二肽基肽酶-4抑制剂相关非炎症性大疱性类天疱疮的临床、实验室及组织学特征

J Clin Med. 2021 Apr 28;10(9):1916. doi: 10.3390/jcm10091916.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验